 | • レポートコード：MRC2303L029 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、258ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査資料によると、動物用医薬品の世界市場規模は2021年に176.8億ドル、2022年に190.5億ドルとなり、その後CAGR 7.90％で成長して2027年までに279.2億ドルに到達する見通しです。本書では、世界の動物用医薬品市場について多面的に調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別分析（ワクチン、動物用医薬品）、製品別分析（抗炎症薬、気管支拡張薬、外部寄生虫駆除剤、内部寄生虫駆除剤）、用途別分析（伴侶動物、家禽）、エンドユーザー別分析（病院、研究室、動物クリニック）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの項目をまとめています。なお、本書には、Aratana Therapeutics, Inc.、Bayer AG、BioPredic International、Boehringer Ingelheim International GmbH、Ceva Animal Health LLC – Biomune、Ceva Sante Animale、Dechra Pharmaceuticals PLC、Dechra Veterinary Products USA、Elanco Animal Health Inc.などの企業情報を掲載しています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の動物用医薬品市場規模：種類別 - ワクチンの市場規模 - 動物用医薬品の市場規模 ・世界の動物用医薬品市場規模：製品別 - 抗炎症薬の市場規模 - 気管支拡張薬の市場規模 - 外部寄生虫駆除剤の市場規模 - 内部寄生虫駆除剤の市場規模 ・世界の動物用医薬品市場規模：用途別 - 伴侶動物における市場規模 - 家禽における市場規模 ・世界の動物用医薬品市場規模：エンドユーザー別 - 病院における市場規模 - 研究室における市場規模 - 動物クリニックにおける市場規模 ・世界の動物用医薬品市場規模：地域別 - 南北アメリカの動物用医薬品市場規模 アメリカの動物用医薬品市場規模 カナダの動物用医薬品市場規模 ブラジルの動物用医薬品市場規模 ... - アジア太平洋の動物用医薬品市場規模 日本の動物用医薬品市場規模 中国の動物用医薬品市場規模 インドの動物用医薬品市場規模 韓国の動物用医薬品市場規模 台湾の動物用医薬品市場規模 ... - ヨーロッパ/中東/アフリカの動物用医薬品市場規模 イギリスの動物用医薬品市場規模 ドイツの動物用医薬品市場規模 フランスの動物用医薬品市場規模 ロシアの動物用医薬品市場規模 ... - その他地域の動物用医薬品市場規模 ・競争状況 ・企業情報 |
The Global Animal Pharmaceuticals Market size was estimated at USD 17.68 billion in 2021 and expected to reach USD 19.05 billion in 2022, and is projected to grow at a CAGR 7.90% to reach USD 27.92 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Animal Pharmaceuticals to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Vaccine and Veterinary Drugs.
Based on Product, the market was studied across Anti-Inflammatories, Bronchodilators, Ectoparasiticides, and Endoparasiticides.
Based on Application, the market was studied across Companion Animal and Poultry.
Based on End User, the market was studied across Hospitals, Laboratories, and Veternary Clinics.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Animal Pharmaceuticals market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Animal Pharmaceuticals Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Animal Pharmaceuticals Market, including Aratana Therapeutics, Inc., Bayer AG, BioPredic International, Boehringer Ingelheim International GmbH, Ceva Animal Health LLC – Biomune, Ceva Sante Animale, Dechra Pharmaceuticals PLC, Dechra Veterinary Products USA, Elanco Animal Health Inc., Eli Lilly & Company, Huvepharma, Inc., Liberty Pharma INC, Merck & Co., Inc., Perrigo Company plc, Sanofi, Sparhawk Laboratories, Vetoquinol S.A., Virbac SA, and Zoetis Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Animal Pharmaceuticals Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Animal Pharmaceuticals Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Animal Pharmaceuticals Market?
4. What is the competitive strategic window for opportunities in the Global Animal Pharmaceuticals Market?
5. What are the technology trends and regulatory frameworks in the Global Animal Pharmaceuticals Market?
6. What is the market share of the leading vendors in the Global Animal Pharmaceuticals Market?
7. What modes and strategic moves are considered suitable for entering the Global Animal Pharmaceuticals Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising adoption of pets across the globe
5.1.1.2. Increasing cases of zoonotic and chronic diseases
5.1.1.3. Livestock population experiencing rapid growth
5.1.1.4. Government mandatory medication and vaccination
5.1.2. Restraints
5.1.2.1. Several risk factors associated with animal health APIs
5.1.3. Opportunities
5.1.3.1. Increasing awareness and expenditure among people regarding animal healthcare
5.1.3.2. Development of new products
5.1.3.3. Unmet animal needs in many countries
5.1.4. Challenges
5.1.4.1. Limited awareness and availability in low-income areas
5.2. Cumulative Impact of COVID-19
6. Animal Pharmaceuticals Market, by Type
6.1. Introduction
6.2. Vaccine
6.3. Veterinary Drugs
7. Animal Pharmaceuticals Market, by Product
7.1. Introduction
7.2. Anti-Inflammatories
7.3. Bronchodilators
7.4. Ectoparasiticides
7.5. Endoparasiticides
8. Animal Pharmaceuticals Market, by Application
8.1. Introduction
8.2. Companion Animal
8.3. Poultry
9. Animal Pharmaceuticals Market, by End User
9.1. Introduction
9.2. Hospitals
9.3. Laboratories
9.4. Veternary Clinics
10. Americas Animal Pharmaceuticals Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Animal Pharmaceuticals Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Animal Pharmaceuticals Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Aratana Therapeutics, Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Bayer AG
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. BioPredic International
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Boehringer Ingelheim International GmbH
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Ceva Animal Health LLC – Biomune
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Ceva Sante Animale
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Dechra Pharmaceuticals PLC
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Dechra Veterinary Products USA
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Elanco Animal Health Inc.
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Eli Lilly & Company
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Huvepharma, Inc.
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Liberty Pharma INC
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Merck & Co., Inc.
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Perrigo Company plc
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Sanofi
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Sparhawk Laboratories
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Vetoquinol S.A.
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Virbac SA
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Zoetis Inc.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing